According to reports from CNBC TV18 and The Economic Times, Onesource Specialty Pharma Ltd. shares plunged as much as 18% to their day's low of ₹1,178 per share on the BSE after the company reported significantly weaker December quarter results. The company's revenue fell 26% year-on-year to ₹290 crore in Q3FY26, compared to ₹392.6 crore in the same quarter last year. The sharp decline was primarily attributed to delays in regulatory approval for semaglutide in Canada, which materially impacted the company's topline performance.
As reported by The Economic Times and CNBC TV18, the company reported a net loss of ₹47 crore in Q3FY26, marking a significant reversal from a profit of ₹67 crore in the corresponding quarter of the previous financial year. EBITDA margins compressed dramatically to 6.0% in Q3FY26 from 36.1% in Q3FY25, representing a decline of 3,018 basis points. EBITDA came in at ₹17 crore, down 88% from ₹142 crore in the same quarter last year, due to lower revenue and largely fixed cost base. The margin compression reflects the impact of the company's fixed cost structure amid declining revenues.
According to The Economic Times, Neeraj Sharma, CEO & MD of Onesource Specialty Pharma, described Q3 as a subdued quarter but emphasized that underlying demand trends remain intact. "As previously anticipated, this has been a subdued quarter due to delays in customer approvals in Canada that have prolonged the transition from the MSA to the CSA phase. The inherent demand, however, remains intact with the order book continuing to trend upwards," Sharma stated. The company highlighted that its order book continues to show an upward trajectory, while interest in the biologics segment is rising. Management noted that the company has onboarded another global biosimilar player, with the funnel at a historic high, reinforcing confidence in its platform capabilities.
As reported by The Economic Times and CNBC TV18, despite the poor quarterly performance, Onesource Specialty Pharma reaffirmed its FY28 financial guidance. The company expects organic revenue of $400 million, which could potentially rise to $500 million including proposed acquisitions. EBITDA margin guidance was maintained at 40%, while the company targets to keep net debt to EBITDA below 1.5x. This guidance represents a significant improvement from current performance levels and demonstrates management's confidence in long-term recovery prospects.
According to The Economic Times, Onesource Specialty Pharma shares have been on a weak run in the first month of 2026, declining over 33% in January and about 41% in the last 6 months. The company expects to benefit from global surge in GLP-1 demand as semaglutide loses patent protection in over 130 countries. The shift towards end-to-end CDMO partnerships and scaling up of the biologics platform are expected to support growth momentum. Management emphasized that over 70% of the business continues to come from existing customers, providing revenue visibility and stability for future quarters despite current headwinds.
